NEW YORK, NY--(Marketwired - Feb 12, 2015) - Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Colorado on behalf of investors who purchased Venaxis, Inc. ("Venaxis" or the "Company") (NASDAQ: APPY) securities between March 13, 2014 and January 28, 2015.

To get more information, click here: There is no cost or obligation to you.

The complaint stems from the Company's January 29, 2015 disclosure that the FDA determined that the APPY1 Test, designed to aid in the identification of patients at low risk for acute appendicitis, "did not meet the criteria for substantial equivalence based on the data and information submitted by the company in its 510(k) submission." The disclosure followed months of positive statements by the Company regarding the APPY1 Test.

If you suffered a loss in Venaxis you have until April 3, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (866) 367-6510